Understand the different stages that are needed to develop a therapy and the many exciting approaches underway.
Target 5000 provides clinical and genotyping services for people living in Ireland with an inherited retinal degeneration.
The pace of research has never been so rapid. We aim to provide you the most up to date news on the advances as they happen.
Get to know the scientists and clinicians who are leading the way into a new era of prevention, detection and treatment for sight loss conditions.
PPI is the working partnership between patients, clinicians, scientists, industry and regulators to advance research and access to therapies.
We are committed to driving the development of therapies and cures, which are accessible to all patients affected by sight loss and the wide spectrum of retinal degenerative disease.